Perspective Therapeutics (CATX)

Overall impact
B (72)

Commentary

Perspective Therapeutics is a strong overall performer. With a 'B' rating of 72.4 for overall impact (85th percentile compared to all companies), Perspective Therapeutics ranks 220th out of 646 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Cell Source and 216 others, and ahead of Pluristem Therapeutics, Viking Therapeutics, Kadmon and 422 others. On top material causes for Perspective Therapeutics's industry (Biotechnology), Perspective Therapeutics performs well in Child and Maternal Health (95.4 score), Child and Maternal Health (95.4), Child and Maternal Health (95.4) and 7 other causes where it received an 'A' score and performs poorly in Decent, Safe Work Opportunities (38.7 score), Decent, Safe Work Opportunities (38.7), Sustainable Use of Water (15.3) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause CATX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2004
Employees
119
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Washington, United States
Share classes
CATX
Description
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Material causes
Ethos considers the following causes material for Perspective Therapeutics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.